

Daniel Q Huang

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/4868609/publications.pdf](https://exaly.com/author-pdf/4868609/publications.pdf)

Version: 2025-02-01

126

peer-reviewed
articles

7,750

peer-reviewed
citations

202408

29

peer-reviewed
h-index

95967

74

g-index

146

documents

8311

doc citations

218533

30

h-index

16722

citing authors

#	ARTICLE	IF	CITATIONS
1	Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study. <i>Hepatology</i> , 2025, 81, 1553-1563.	10.1	27
2	Prevalence of Chronic Liver Disease in Cholangiocarcinoma: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2025, 23, 1710-1718.	6.0	2
3	Prevalence of Low FIB-4 in MASLD-Related Hepatocellular Carcinoma: A Multicentre Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2025, 61, 278-285.	3.7	18
4	A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2025, 61, 456-464.	3.7	20
5	Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis. <i>Hepatology</i> , 2025, 82, 1523-1533.	10.1	68
6	Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on "Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021". <i>Clinical and Molecular Hepatology</i> , 2025, 31, 654-657.	8.8	1
7	The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021. <i>Liver International</i> , 2025, 45, .	4.0	37
8	Metabolic dysfunction-associated steatotic liver disease in adults. <i>Nature Reviews Disease Primers</i> , 2025, 11, .	47.2	187
9	Metabolic Cause of Cirrhosis Is the Emerging Etiology for Primary Liver Cancer in the Asia-Oceania Region: Analysis of Global Burden of Disease (GBD) Study 2021. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2025, 40, 1188-1201.	2.5	9
10	Global Health Policies for Hepatocellular Carcinoma: A Cross-Sectional Study. <i>Clinical Gastroenterology and Hepatology</i> , 2025, 24, 1464-1466.e3.	6.0	2
11	Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2025, 62, 349-358.	3.7	4
12	Meta-Analysis: Effects of Steatotic Liver Disease-Associated Genetic Risk Alleles on Longitudinal Outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2025, 62, 244-276.	3.7	11
13	NASH is the Leading Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2024, 22, 197-199.e3.	6.0	40
14	NAFLD and NAFLD-related HCC in Asia: Burden and Surveillance. <i>Journal of Clinical and Experimental Hepatology</i> , 2024, 14, 101213.	2.3	11
15	Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 80-88.	3.7	23
16	Cost-Effectiveness Analysis of Hepatocellular Carcinoma Surveillance in Nonalcoholic Fatty Liver Disease Cirrhosis Using US Visualization Score-Triggered Abbreviated MRI. <i>American Journal of Gastroenterology</i> , 2024, 119, 1326-1336.	0.7	16
17	Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 742-751.	3.7	7
18	Meta-Analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 730-741.	3.7	19

#	ARTICLE	IF	CITATIONS
19	Upper limit of normal ALT levels in health and metabolic diseases: Pooled analysis of 423,355 individuals with bootstrap modelling. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 984-992.	3.7	11
20	Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease. <i>Hepatology Research</i> , 2024, 54, 753-762.	2.9	20
21	Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study. <i>Liver International</i> , 2024, 44, 1316-1328.	4.0	19
22	MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH. <i>Gut</i> , 2024, 73, 1343-1349.	16.8	35
23	Changing global epidemiology of chronic hepatitis C virus-related outcomes from 2010 to 2019: cirrhosis is the growing burden of hepatitis C virus-related disease. <i>European Journal of Cancer Prevention</i> , 2024, 33, 512-524.	2.0	7
24	Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 1521-1526.	3.7	7
25	Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019. <i>Hepatology</i> , 2024, 80, 828-843.	10.1	40
26	Repeatability of vibration-controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 60, 484-491.	3.7	8
27	Socioeconomic association of alcohol use disorder and cardiovascular and alcohol-associated liver disease from 2010 to 2019. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 60, 340-349.	3.7	34
28	Optimizing care of HBV infection and HBV-related HCC. <i>Clinical Liver Disease</i> , 2024, 23, .	1.3	1
29	Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2024, 21, 834-851.	45.9	134
30	Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 45-54.e6.	6.0	43
31	Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 538-540.e4.	6.0	7
32	UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1475-1484.	6.0	68
33	Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 931-939.e5.	6.0	171
34	Future anti-HDV treatment strategies, including those aimed at HBV functional cure. <i>Liver International</i> , 2023, 43, 1157-1169.	4.0	9
35	Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2682-2685.e4.	6.0	39
36	Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH. <i>Hepatology</i> , 2023, 77, 1150-1163.	10.1	125

#	ARTICLE	IF	CITATIONS
37	Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. <i>Gut</i> , 2023, 72, 581-589.	16.8	89
38	Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 37-51.	3.7	52
39	Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2023, 17, 24-33.	2.8	31
40	Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 600-609.	3.7	77
41	Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis. <i>Hepatology</i> , 2023, 77, 1746-1756.	10.1	16
42	The prognostic value of including non-alcoholic fatty liver disease in the definition of metabolic syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 979-987.	3.7	23
43	Racial and Ethnic Disparities in Characteristics and Care Patterns of Chronic Hepatitis B Patients in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2606-2615.e7.	6.0	8
44	The Past, Present, and Future of Noninvasive Test in Chronic Liver Diseases. <i>Medical Clinics of North America</i> , 2023, 107, 397-421.	3.1	3
45	Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study. <i>JHEP Reports</i> , 2023, 5, 100692.	4.5	20
46	A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes. <i>Cancer Research</i> , 2023, 83, 428-440.	3.8	11
47	Global treatment rate and barriers to direct-acting antiviral therapy: A systematic review and meta-analysis of 146 studies and 1,760,352 hepatitis C virus patients. <i>Liver International</i> , 2023, 43, 1195-1203.	4.0	15
48	Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 404-407.	8.8	3
49	Global epidemiology of cirrhosis – aetiology, trends and predictions. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 388-398.	45.9	681
50	Global burden of hepatitis B virus: current status, missed opportunities and a call for action. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 524-537.	45.9	496
51	Ethnic disparities in waitlist outcomes of patients with nonalcoholic steatohepatitis listed for liver transplantation in the US. <i>Liver Transplantation</i> , 2023, 29, 1181-1191.	2.5	9
52	Utilization of Antiviral Therapy for Patients With Hepatitis B-Related Hepatocellular Carcinoma: A Nationwide Real-World US Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 3305-3313.e4.	6.0	12
53	Meta-analysis: Prevalence of significant or advanced fibrosis in adults with alpha-1 antitrypsin deficiency. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 152-158.	3.7	9
54	Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 229-237.	3.7	16

#	ARTICLE	IF	CITATIONS
55	Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase. <i>Hepatology</i> , 2023, 78, 1558-1568.	10.1	86
56	Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 585-592.	3.7	24
57	Response to Paik et al. on the disease burden of NAFLD. <i>Cell Metabolism</i> , 2023, 35, 1089-1090.	25.2	4
58	Chemoprevention in hepatocellular carcinoma. <i>Current Hepatology Reports</i> , 2023, 22, 108-117.	0.6	1
59	Hepatocellular carcinoma surveillance "utilization, barriers and the impact of changing aetiology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 797-809.	45.9	168
60	Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Advances in Therapy</i> , 2023, 40, 4805-4816.	3.3	4
61	The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 1062-1074.	3.7	30
62	MEFIB index and MAST score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease: Individual participant data meta-analyses. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 856-865.	3.7	18
63	Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study. <i>Hepatology International</i> , 2023, 18, 540-549.	4.2	7
64	Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1803-1812.e5.	6.0	115
65	Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. <i>Journal of Hepatology</i> , 2022, 76, 63-74.	4.2	46
66	Meta-analysis and systematic review: Prevalence, graft failure, mortality, and postoperative thrombosis in liver transplant recipients with preoperative portal vein thrombosis. <i>Clinical Transplantation</i> , 2022, 36, .	1.7	24
67	A Diagnostic Test Meta-Analysis Evaluating Imaging-Based and Blood Biomarker-Based Assessment Tools for Fibrosis After Liver Transplantation. <i>Liver Transplantation</i> , 2022, 28, 659-669.	2.5	9
68	Global Prevalence, Risk Factors, and Outcomes of Depression After Liver Transplant: A Systematic Review and Meta-analysis. <i>Gastro Hep Advances</i> , 2022, 1, 150-159.	1.1	9
69	2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2809-2817.e28.	6.0	583
70	Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 820-827.	3.7	55
71	Review article: current and emerging therapies for the management of cirrhosis and its complications. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1099-1115.	3.7	35
72	Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1076-1087.	3.7	27

#	ARTICLE	IF	CITATIONS
73	Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies. <i>Hepatology Communications</i> , 2022, 6, 1813-1826.	4.5	77
74	Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2022, 52, 497-507.	2.9	54
75	Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12,620,736 Individuals. <i>Endocrine Practice</i> , 2022, 28, 667-672.	3.3	62
76	Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. <i>Lancet Oncology</i> , 2022, 23, 521-530.	27.4	274
77	A systematic review and meta-analysis on the impact of pre-existing and new-onset atrial fibrillation on outcomes before and after liver transplantation. <i>Digestive and Liver Disease</i> , 2022, 54, 614-621.	2.5	16
78	The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 565-574.	8.8	76
79	Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. <i>Cell Metabolism</i> , 2022, 34, 969-977.e2.	25.2	473
80	Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus. <i>JAMA Network Open</i> , 2022, 5, e2219407.	6.6	42
81	Shared Mechanisms between Cardiovascular Disease and NAFLD. <i>Seminars in Liver Disease</i> , 2022, 42, 455-464.	3.2	34
82	Impact of advanced practice providers on characteristics and quality of care of patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 1591-1601.	3.7	6
83	Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 20, 37-49.	45.9	436
84	Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States. <i>JAMA Network Open</i> , 2022, 5, e2245424.	6.6	51
85	Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. <i>Journal of Medical Virology</i> , 2021, 93, 1449-1458.	3.7	573
86	Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2021, 5, 122-132.	4.5	26
87	A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity. <i>Journal of Clinical Medicine</i> , 2021, 10, 238.	2.5	43
88	Defining Age-Related Thresholds for ALT and the Risk of Confounders. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 20, 715-716.	6.0	0
89	A Time-Based Meta-Analysis on the Incidence of New Onset Diabetes after Liver Transplantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 1045.	2.5	9
90	Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study. <i>Cancers</i> , 2021, 13, 1308.	3.8	68

#	ARTICLE	IF	CITATIONS
91	Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 1922-1932.	4.0	27
92	Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. <i>Hepatology</i> , 2021, 74, 656-666.	10.1	39
93	Letter to the Editor: Hepatocellular Carcinoma Surveillance in Cirrhosis Patients: Is the Real-World Situation Even Worse Than Reported?. <i>Hepatology</i> , 2021, 74, 1714-1715.	10.1	5
94	HBV-related hepatocellular carcinoma: A call to improve surveillance and linkage to care. <i>Liver International</i> , 2021, 41, 2238-2239.	4.0	3
95	A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis. <i>Hepatology International</i> , 2021, 15, 1196-1206.	4.2	38
96	Letter: hepatocellular carcinoma risk in patients with non-selective beta blockers. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1093-1094.	3.7	2
97	Cost-effectiveness of HCC surveillance among HCV patients after sustained virological response with direct-acting antivirals. <i>Liver International</i> , 2021, 41, 3036-3037.	4.0	0
98	Impact of COVID-19 on Liver Transplantation in Hong Kong and Singapore: A Modelling Study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 16, 100262.	3.4	4
99	Controversies in Treating Chronic Hepatitis B virus. <i>Clinics in Liver Disease</i> , 2021, 25, 763-784.	3.5	1
100	Novel albumin, bilirubin and platelet criteria for the exclusion of high-risk varices in compensated advanced chronic liver disease: A validation study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101598.	1.8	4
101	Predicting HCC Response to Multikinase Inhibitors With In-Vivo Cirrhotic Mouse Model for Personalized Therapy. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1313-1325.	5.6	17
102	Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg). <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 172-182.	3.7	29
103	A Multiethnic Asian Perspective of Presumed Consent for Organ Donation: A Population-Based Perception Study. <i>Frontiers in Public Health</i> , 2021, 9, .	2.7	8
104	A meta-analysis of the cumulative incidence, risk factors, and clinical outcomes associated with chronic kidney disease after liver transplantation. <i>Transplant International</i> , 2021, 34, 2524-2533.	2.0	15
105	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2021, 16, 48-58.	4.2	18
106	ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. <i>Hepatology Communications</i> , 2020, 4, 1624-1636.	4.5	25
107	Extraction of intra-biliary hepatocellular carcinoma by endoscopic retrograde cholangiopancreatography. <i>BMC Gastroenterology</i> , 2020, 20, .	2.2	2
108	Liver Care and Surveillance: The Global Impact of the COVID-19 Pandemic. <i>Hepatology Communications</i> , 2020, 4, 1751-1757.	4.5	53

#	ARTICLE	IF	CITATIONS
109	Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 739-752.	22.9	779
110	Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≥ 5 cm) after initial curative resection. <i>European Radiology</i> , 2020, 30, 6357-6368.	3.6	45
111	Hepatitis B: Who to treat? A critical review of international guidelines. <i>Liver International</i> , 2020, 40, 5-14.	4.0	32
112	Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 18, 223-238.	45.9	1,615
113	Life After s Loss: Impact of Hepatitis B s Antigen Loss on Future Patient Outcomes. <i>Clinical Liver Disease</i> , 2020, 16, 262-265.	1.3	4
114	A murine model demonstrating reversal of structural and functional correlates of cirrhosis with progenitor cell transplantation. <i>Scientific Reports</i> , 2019, 9, .	3.4	13
115	Editorial on "Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study". <i>Clinical and Molecular Hepatology</i> , 0, 32, 407-409.	8.8	2
116	Broadening PEth testing for alcohol exposure in the Asia-Pacific region. <i>Journal of Hepatology</i> , 0, 83, e229-e231.	4.2	2
117	Incidence of Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Reconstructed Individual Patient Data Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 0, 24, 1236-1246.	6.0	3
118	Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide Analogs. <i>Journal of Viral Hepatitis</i> , 0, 32, .	1.9	0
119	Meta-Analysis: Utilisation of Hepatocellular Carcinoma Surveillance. <i>Alimentary Pharmacology and Therapeutics</i> , 0, 63, 8-16.	3.7	3
120	Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302 Td (MASLD) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 292 Td	3.7	5
121	Plasma inflammatory proteome profiles identify MASLD among children with overweight or obesity. <i>Cardiovascular Diabetology</i> , 0, 24, .	9.4	0
122	Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities. <i>Gut</i> , 0, 75, 815-825.	16.8	6
123	PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a	3.7	3
124	Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution. <i>Alimentary Pharmacology and Therapeutics</i> , 0, 63, 922-931.	3.7	1
125	Rethinking "Safe" Drinking: A Review of the Carcinogenic Risks of Alcohol Consumption. <i>Current Hepatology Reports</i> , 0, 25, .	0.6	0
126	Abstract 936: Temporal dependency of STAT3 signaling dictates hepatocarcinogenesis in metabolic dysfunction-associated steatohepatitis.. <i>Cancer Research</i> , 0, 86, 936-936.	3.8	0